Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
Edward M. Kaye, M.D., has been appointed to the company’s Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of
Dr. Kaye joins the Cytokinetics Board of Directors with substantial industry experience in rare diseases including neurological conditions. He has served as Interim Chief Executive Officer of Sarepta since 2015 and as the SVP, Chief Medical Officer since 2011. Prior to joining Sarepta, Dr. Kaye was employed by
“We are pleased to welcome Ed to our Board. His expertise in rare neuromuscular diseases is highly relevant as we advance our clinical programs in ALS and SMA into late-stage development,” said
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “Ed has overseen many clinical research and development programs, and we look forward to the benefit of his industry-leading experience.”
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy and chronic obstructive pulmonary disease. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. For additional information about
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").